TABLE 3.

Combination therapy with targeted and anti-angiogenic agents in second-line nonsmall cell lung cancer

First author, year [ref.]	Phase	Patients	Arms	PFS months	p-value	OS months	p-value	Response rate %	p-value
Herbst, 2011 [58]	III	636	Erlotinib + bevacizumab	3.4		9.2		13
			Erlotinib + placebo	1.7		9.3		6
Scagliotti, 2012 [60]	III	960	Erlotinib + sunitinib	3.6	0.0023	9.0	0.1388	10.6	0.0471
			Erlotinib + placebo	2.0		8.5		6.9
Spigel, 2011 [62]	II	168	Erlotinib + sorafenib	3.38	0.196	7.62	0.29	8.0	0.56
			Erlotinib + placebo	1.94		7.23		11.0
Besse, 2013 [66]	II	133	Erlotinib + everolimus	2.9	0.228	9.1		12.1
			Erlotinib	2.0		9.7		10.4
Price, 2010 [65]	II	31	Gefitinib + everolimus			11.0		9.6
Sequist, 2011 [68]	II	167	Erlotinib + tivantinib	3.8	0.24	8.5	0.47	10	ns
			Erlotinib + placebo	2.3		6.9		7
Ramalingam, 2011 [70]	II	172	Erlotinib + R1507 weekly	1.9		8.1		8.8
			Erlotinib + R1507 every 3 weeks	2.7	0.67	8.1	0.48	7.0
			Erlotinib + placebo	1.5	0.73	12.1	0.04	8.8

Data are presented as n, unless otherwise stated. PFS: progression-free survival; OS: overall survival; ns: non significant.